Wall Street Zen Downgrades Theravance Biopharma (NASDAQ:TBPH) to Buy

Theravance Biopharma (NASDAQ:TBPH) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other brokerages have also issued reports on TBPH. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. HC Wainwright lifted their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. TD Cowen lifted their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, March 24th. Finally, Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Stock Up 2.9%

Shares of NASDAQ:TBPH opened at $16.56 on Monday. The firm has a fifty day moving average of $16.91 and a two-hundred day moving average of $17.02. The firm has a market capitalization of $852.72 million, a P/E ratio of 8.16 and a beta of 0.17. Theravance Biopharma has a 12-month low of $8.09 and a 12-month high of $21.03.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Theravance Biopharma by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp lifted its stake in shares of Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after purchasing an additional 45,987 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after purchasing an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Theravance Biopharma by 12.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after purchasing an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma in the 3rd quarter valued at $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.